公开(公告)号：US20250064720A1

公开(公告)日：2025-02-27

申请号：US18887827

申请日：2024-09-17

Applicant: SHILPA MEDICARE LIMITED

Inventor： Vara Prasad RANGABHATLA GUNNESWARA SUBRAMANYA ,  Sai Laxmi Aparna RANGABHATLA ,  Ratna Phani AYALASOMAYAJULA

IPC: A61K9/00 ,  A61K9/12 ,  A61K31/195 ,  A61K47/36

Abstract: The present invention relates to novel formulations comprising a sprayable composition comprising tranexamic acid and chitosan for use in the treatment of wounds or injuries, in particular for use as a topical hemostatic composition or for surgical intervention and the process for preparation thereof.

公开(公告)号：US12187828B2

公开(公告)日：2025-01-07

申请号：US18129811

申请日：2023-03-31

Applicant: The Board of Trustees of the Leland Stanford Junior University

Inventor： Eric A. Appel ,  Caitlin Maikawa ,  Joseph L. Mann

IPC: A61K9/12 ,  A61K9/127 ,  A61K9/51 ,  C08F220/36

Abstract: A polyacrylamide-based copolymer reduces or prevents aggregation of biologic molecules including proteins, peptides, and nucleic acids, and lipid-based vehicles such as liposomes, lipid nanoparticles, polymerosomes, and micelles, in aqueous formulations at hydrophobic interfaces, thereby increasing the thermal stability of the molecules in the formulation. Methods and compositions comprising the copolymer and a protein or the copolymer and insulin can be used for treating conditions including diabetes.

公开(公告)号：US20250002514A1

公开(公告)日：2025-01-02

申请号：US18273841

申请日：2022-01-25

Applicant: Microbion Corporation

Inventor： Jeffrey W. MILLARD ,  Brett Hugh James BAKER

IPC: C07F9/94 ,  A61K9/00 ,  A61K9/12 ,  A61K31/555 ,  A61K47/26 ,  A61P17/02 ,  A61P31/04

Abstract: The invention relates to an amorphous form of bismuth-1,2-ethanedithiol (BisEDT). Methods of making amorphous BisEDT and methods of use are also provided.

公开(公告)号：US20240424032A1

公开(公告)日：2024-12-26

申请号：US18824109

申请日：2024-09-04

Applicant: AOBIOME LLC

Inventor： David R. Whitlock ,  Larry Weiss

IPC: A61K35/74 ,  A61K9/00 ,  A61K9/12 ,  A61K9/16 ,  A61L27/36 ,  A61P31/04

Abstract: A method for degrading a biofilm on a surface is provided. A method of preventing formation of a biofilm on a surface is provided. The method includes administering, e.g., applying, ammonia oxidizing microorganisms, e.g., a preparation comprising ammonia oxidizing bacteria, to the surface. Preparations comprising ammonia oxidizing microorganisms for biofilm treatment are also provided.

公开(公告)号：US12171867B2

公开(公告)日：2024-12-24

申请号：US17712764

申请日：2022-04-04

Applicant: CDA Research Group, Inc.

Inventor： ChunLim Abbott ,  Dominic C. Abbott

IPC: A61K33/34 ,  A61K9/00 ,  A61K9/02 ,  A61K9/06 ,  A61K9/08 ,  A61K9/12 ,  A61K9/70 ,  A61L17/00 ,  A61L24/02

Abstract: A topical copper ion treatment in basic form composes a copper ion-containing solution composed of a biocompatible solution containing copper ions obtained by leaching of the copper ions from copper metal into the solution. The copper ion-containing solution can be combined with various carriers to form various forms of the copper ion treatment including creams, gels, lotions, foams, pastes, tampons, solutions, suppositories, body wipes, wound dressings, skin patches, and suture material. A method of making the copper ion-containing solution involves placing solid copper metal in a quantity of a biocompatible solution and maintaining the solution at a specified temperature for a predetermined period of time during which copper ions each from the copper metal into the solution, and thereafter separating the solution from the solid copper metal.

公开(公告)号：US12150921B2

公开(公告)日：2024-11-26

申请号：US18334690

申请日：2023-06-14

Applicant: Bryn Pharma, LLC

Inventor： Steven Hartman ,  Michelle Lobel ,  Matthew P. Robben ,  Kenneth L. Dretchen ,  Michael Mesa

IPC: A61K31/137 ,  A61K9/00 ,  A61K9/08 ,  A61K9/12 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20 ,  A61K47/38 ,  A61M11/00 ,  A61M15/08 ,  A61P37/08

Abstract: Provided herein are epinephrine spray formulations. Also provided herein are methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatment.

公开(公告)号：US20240374576A1

公开(公告)日：2024-11-14

申请号：US18670960

申请日：2024-05-22

Applicant: ARCUTIS BIOTHERAPEUTICS, INC.

Inventor： David W. Osborne

IPC: A61K31/44 ,  A61K9/00 ,  A61K9/06 ,  A61K9/12 ,  A61K45/06 ,  A61K47/10 ,  A61K47/24 ,  A61P19/02

Abstract: A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax. The spike in Cmax is reduced by topically administering the PDE-4 inhibitor in combination with one or more phosphate ester surfactants. Reducing the spike in Cmax will reduce gastrointestinal side effects and result in better patient compliance.

公开(公告)号：US20240316094A1

公开(公告)日：2024-09-26

申请号：US18680557

申请日：2024-05-31

Applicant: Porosome Therapeutics, Inc.

Inventor： Bhanu Pratap Jena

IPC: A61K31/724 ,  A61K9/00 ,  A61K9/12 ,  A61K31/352 ,  A61K33/30 ,  A61K47/02 ,  A61K47/18

CPC classification number: A61K31/724 ,  A61K9/008 ,  A61K9/12 ,  A61K31/352 ,  A61K33/30 ,  A61K47/02 ,  A61K47/186

Abstract: The invention provides the use of a formulation containing cyclodextrin, quercetin and zinc, at appropriate concentrations to mitigate infections by enveloped viruses like SARS-CoV-2, influenza and HIV/AIDS, when administered via pulmonary and dermal route. While the different forms of cyclodextrin prevent the entry of coated virus into host cells by extracting and sequestering cholesterol molecules at the virus coat and at the host cell plasma membrane, the natural plant-based ionophore quercetin in the formulation, enables cellular entry of zinc, inhibiting viral replication by altering polymerase activity in the host cell. Hence cyclodextrin, and quercetin plus zinc, either in combination or in tandem order of administration, serves both as prophylactic and therapeutic.

公开(公告)号：US12065449B2

公开(公告)日：2024-08-20

申请号：US18547958

申请日：2022-02-24

Applicant: SYNESIS LLC

Inventor： Jess D. Reed ,  Daniel Alfredo Esquivel-Alvarado ,  Emilia Alfaro-Viquez ,  Christian G. Krueger

IPC: A61K9/20 ,  A61K9/00 ,  A61K9/06 ,  A61K9/12 ,  A61K9/48 ,  C07D519/00 ,  G01N33/569

CPC classification number: C07D519/00 ,  A61K9/0019 ,  A61K9/06 ,  A61K9/124 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866 ,  G01N33/56916 ,  G01N2333/245 ,  G01N2469/10

Abstract: Proanthocyanidin-cinnamaldehydes pyrylium products (FP) were synthesized by the condensation reaction of proanthocyanidins (PAC) with various cinnamaldehydes. Synthesized FP exhibited fluorescence at higher excitation and emission wavelengths than PAC. FP were evaluated for their ability to agglutinate extra-intestinal pathogenic Escherichia coli (ExPEC). Results showed that FP were significantly more bioactive (p-value

公开(公告)号：US12053508B2

公开(公告)日：2024-08-06

申请号：US17891835

申请日：2022-08-19

Applicant: Hybrid Medical, LLC

Inventor： Jeffry Twidwell ,  Joel Buckley ,  Harold Hoium

IPC: A61K38/44 ,  A61K9/00 ,  A61K9/06 ,  A61K9/12 ,  A61K31/277 ,  A61K31/40 ,  A61K31/4422 ,  A61K31/554 ,  A61K35/57 ,  A61K38/21 ,  A61K45/06 ,  A61K47/24 ,  C07D211/90

CPC classification number: A61K38/446 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/12 ,  A61K31/277 ,  A61K31/40 ,  A61K31/4422 ,  A61K31/554 ,  A61K35/57 ,  A61K38/21 ,  A61K38/212 ,  A61K45/06 ,  A61K47/24 ,  C07D211/90 ,  C12Y115/01001 ,  A61K38/446 ,  A61K2300/00 ,  A61K31/4422 ,  A61K2300/00 ,  A61K31/554 ,  A61K2300/00 ,  A61K31/277 ,  A61K2300/00 ,  A61K31/40 ,  A61K2300/00 ,  A61K35/57 ,  A61K2300/00 ,  A61K38/212 ,  A61K2300/00

Abstract: The invention provides topical compositions and methods for using the compositions. The compositions can be used for the treatment of fibrotic or connective tissue disorders involving scarring, sub-dermal plaque accumulations, or fibrosis of muscle tissue. The disorders can be painlessly treated by the topical application of a composition described herein. One or more calcium channel blocker agents can serve as an active ingredient of the compositions, optionally in combination with, for example, one or more of emu oil and superoxide dismutase. The composition can further include pharmaceutically acceptable carriers that can facilitate the non-invasive transdermal delivery of the active(s) to subdermal sites.